{"id":63753,"date":"2026-04-22T22:42:20","date_gmt":"2026-04-22T14:42:20","guid":{"rendered":"https:\/\/flcube.com\/?p=63753"},"modified":"2026-04-22T22:42:22","modified_gmt":"2026-04-22T14:42:22","slug":"mercks-idvynso-gains-fda-approval-as-novel-dual-drug-hiv-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63753","title":{"rendered":"Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment"},"content":{"rendered":"\n

Merck & Co., Inc.<\/strong> (MSD, NYSE: MRK<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has granted marketing approval for Idvynso<\/strong>, a dual-drug single-tablet regimen<\/strong> for adults with HIV-1 infection<\/strong> who are virologically suppressed and meet specific criteria.<\/p>\n\n\n\n

Regulatory Approval Details<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Indication<\/strong><\/td>Adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA <50 copies\/mL) on stable antiretroviral therapy<\/td><\/tr>
Patient Criteria<\/strong><\/td>No history of virologic failure; no known doravirine-associated resistance mutations<\/td><\/tr>
Usage<\/strong><\/td>Replacement for current antiretroviral regimen<\/td><\/tr>
Composition<\/strong><\/td>100 mg doravirine + 0.25 mg islatravir<\/td><\/tr>
Approval Date<\/strong><\/td>April 22, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Mechanism & Differentiation<\/h2>\n\n\n\n